table of content
1 Introduction to Research & Analysis Reports
1.1 Cancer Minimal Residual Disease Testing Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cancer Minimal Residual Disease Testing Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cancer Minimal Residual Disease Testing Overall Market Size
2.1 Global Cancer Minimal Residual Disease Testing Market Size: 2022 VS 2029
2.2 Global Cancer Minimal Residual Disease Testing Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Cancer Minimal Residual Disease Testing Sales: 2018-2029
3 Company Landscape
3.1 Top Cancer Minimal Residual Disease Testing Players in Global Market
3.2 Top Global Cancer Minimal Residual Disease Testing Companies Ranked by Revenue
3.3 Global Cancer Minimal Residual Disease Testing Revenue by Companies
3.4 Global Cancer Minimal Residual Disease Testing Sales by Companies
3.5 Global Cancer Minimal Residual Disease Testing Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Cancer Minimal Residual Disease Testing Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Cancer Minimal Residual Disease Testing Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cancer Minimal Residual Disease Testing Players in Global Market
3.8.1 List of Global Tier 1 Cancer Minimal Residual Disease Testing Companies
3.8.2 List of Global Tier 2 and Tier 3 Cancer Minimal Residual Disease Testing Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Cancer Minimal Residual Disease Testing Market Size Markets, 2022 & 2029
4.1.2 Flow Cytometry
4.1.3 Polymerase Chain Reaction (PCR)
4.1.4 Next-Generation Sequencing (NGS)
4.1.5 Other
4.2 By Type - Global Cancer Minimal Residual Disease Testing Revenue & Forecasts
4.2.1 By Type - Global Cancer Minimal Residual Disease Testing Revenue, 2018-2023
4.2.2 By Type - Global Cancer Minimal Residual Disease Testing Revenue, 2024-2029
4.2.3 By Type - Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
4.3 By Type - Global Cancer Minimal Residual Disease Testing Sales & Forecasts
4.3.1 By Type - Global Cancer Minimal Residual Disease Testing Sales, 2018-2023
4.3.2 By Type - Global Cancer Minimal Residual Disease Testing Sales, 2024-2029
4.3.3 By Type - Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
4.4 By Type - Global Cancer Minimal Residual Disease Testing Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Cancer Minimal Residual Disease Testing Market Size, 2022 & 2029
5.1.2 Hematological Malignancies
5.1.3 Leukemia
5.1.4 Lymphoma
5.1.5 Solid Tumors
5.1.6 Other
5.2 By Application - Global Cancer Minimal Residual Disease Testing Revenue & Forecasts
5.2.1 By Application - Global Cancer Minimal Residual Disease Testing Revenue, 2018-2023
5.2.2 By Application - Global Cancer Minimal Residual Disease Testing Revenue, 2024-2029
5.2.3 By Application - Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
5.3 By Application - Global Cancer Minimal Residual Disease Testing Sales & Forecasts
5.3.1 By Application - Global Cancer Minimal Residual Disease Testing Sales, 2018-2023
5.3.2 By Application - Global Cancer Minimal Residual Disease Testing Sales, 2024-2029
5.3.3 By Application - Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
5.4 By Application - Global Cancer Minimal Residual Disease Testing Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Cancer Minimal Residual Disease Testing Market Size, 2022 & 2029
6.2 By Region - Global Cancer Minimal Residual Disease Testing Revenue & Forecasts
6.2.1 By Region - Global Cancer Minimal Residual Disease Testing Revenue, 2018-2023
6.2.2 By Region - Global Cancer Minimal Residual Disease Testing Revenue, 2024-2029
6.2.3 By Region - Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
6.3 By Region - Global Cancer Minimal Residual Disease Testing Sales & Forecasts
6.3.1 By Region - Global Cancer Minimal Residual Disease Testing Sales, 2018-2023
6.3.2 By Region - Global Cancer Minimal Residual Disease Testing Sales, 2024-2029
6.3.3 By Region - Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.4.2 By Country - North America Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.4.3 US Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.4.4 Canada Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.4.5 Mexico Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.5.2 By Country - Europe Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.5.3 Germany Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.4 France Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.5 U.K. Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.6 Italy Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.7 Russia Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.8 Nordic Countries Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.9 Benelux Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.6.2 By Region - Asia Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.6.3 China Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.4 Japan Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.5 South Korea Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.6 Southeast Asia Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.7 India Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.7.2 By Country - South America Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.7.3 Brazil Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.7.4 Argentina Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.8.3 Turkey Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8.4 Israel Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8.5 Saudi Arabia Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8.6 UAE Cancer Minimal Residual Disease Testing Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Adaptive Biotechnologies Corporation
7.1.1 Adaptive Biotechnologies Corporation Company Summary
7.1.2 Adaptive Biotechnologies Corporation Business Overview
7.1.3 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Major Product Offerings
7.1.4 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.1.5 Adaptive Biotechnologies Corporation Key News & Latest Developments
7.2 ArcherDX, Inc. (Invitae Corporation)
7.2.1 ArcherDX, Inc. (Invitae Corporation) Company Summary
7.2.2 ArcherDX, Inc. (Invitae Corporation) Business Overview
7.2.3 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Major Product Offerings
7.2.4 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.2.5 ArcherDX, Inc. (Invitae Corporation) Key News & Latest Developments
7.3 Asuragen
7.3.1 Asuragen Company Summary
7.3.2 Asuragen Business Overview
7.3.3 Asuragen Cancer Minimal Residual Disease Testing Major Product Offerings
7.3.4 Asuragen Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.3.5 Asuragen Key News & Latest Developments
7.4 Arup Laboratories
7.4.1 Arup Laboratories Company Summary
7.4.2 Arup Laboratories Business Overview
7.4.3 Arup Laboratories Cancer Minimal Residual Disease Testing Major Product Offerings
7.4.4 Arup Laboratories Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.4.5 Arup Laboratories Key News & Latest Developments
7.5 Bio-Rad Laboratories
7.5.1 Bio-Rad Laboratories Company Summary
7.5.2 Bio-Rad Laboratories Business Overview
7.5.3 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Major Product Offerings
7.5.4 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.5.5 Bio-Rad Laboratories Key News & Latest Developments
7.6 Cergentis B.V.
7.6.1 Cergentis B.V. Company Summary
7.6.2 Cergentis B.V. Business Overview
7.6.3 Cergentis B.V. Cancer Minimal Residual Disease Testing Major Product Offerings
7.6.4 Cergentis B.V. Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.6.5 Cergentis B.V. Key News & Latest Developments
7.7 F. Hoffmann- La Roche Ltd
7.7.1 F. Hoffmann- La Roche Ltd Company Summary
7.7.2 F. Hoffmann- La Roche Ltd Business Overview
7.7.3 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Major Product Offerings
7.7.4 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.7.5 F. Hoffmann- La Roche Ltd Key News & Latest Developments
7.8 Guardant Health
7.8.1 Guardant Health Company Summary
7.8.2 Guardant Health Business Overview
7.8.3 Guardant Health Cancer Minimal Residual Disease Testing Major Product Offerings
7.8.4 Guardant Health Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.8.5 Guardant Health Key News & Latest Developments
7.9 ICON plc
7.9.1 ICON plc Company Summary
7.9.2 ICON plc Business Overview
7.9.3 ICON plc Cancer Minimal Residual Disease Testing Major Product Offerings
7.9.4 ICON plc Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.9.5 ICON plc Key News & Latest Developments
7.10 Invivoscribe
7.10.1 Invivoscribe Company Summary
7.10.2 Invivoscribe Business Overview
7.10.3 Invivoscribe Cancer Minimal Residual Disease Testing Major Product Offerings
7.10.4 Invivoscribe Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.10.5 Invivoscribe Key News & Latest Developments
7.11 Laboratory Corporation of America Holdings
7.11.1 Laboratory Corporation of America Holdings Company Summary
7.11.2 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Business Overview
7.11.3 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Major Product Offerings
7.11.4 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.11.5 Laboratory Corporation of America Holdings Key News & Latest Developments
7.12 Mission Bio
7.12.1 Mission Bio Company Summary
7.12.2 Mission Bio Cancer Minimal Residual Disease Testing Business Overview
7.12.3 Mission Bio Cancer Minimal Residual Disease Testing Major Product Offerings
7.12.4 Mission Bio Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.12.5 Mission Bio Key News & Latest Developments
7.13 Natera, Inc.
7.13.1 Natera, Inc. Company Summary
7.13.2 Natera, Inc. Cancer Minimal Residual Disease Testing Business Overview
7.13.3 Natera, Inc. Cancer Minimal Residual Disease Testing Major Product Offerings
7.13.4 Natera, Inc. Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.13.5 Natera, Inc. Key News & Latest Developments
7.14 NeoGenomics Laboratories
7.14.1 NeoGenomics Laboratories Company Summary
7.14.2 NeoGenomics Laboratories Business Overview
7.14.3 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Major Product Offerings
7.14.4 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.14.5 NeoGenomics Laboratories Key News & Latest Developments
7.15 Opko Health
7.15.1 Opko Health Company Summary
7.15.2 Opko Health Business Overview
7.15.3 Opko Health Cancer Minimal Residual Disease Testing Major Product Offerings
7.15.4 Opko Health Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.15.5 Opko Health Key News & Latest Developments
7.16 Quest Diagnostics Incorporated
7.16.1 Quest Diagnostics Incorporated Company Summary
7.16.2 Quest Diagnostics Incorporated Business Overview
7.16.3 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Major Product Offerings
7.16.4 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.16.5 Quest Diagnostics Incorporated Key News & Latest Developments
7.17 Sysmex Corporation
7.17.1 Sysmex Corporation Company Summary
7.17.2 Sysmex Corporation Business Overview
7.17.3 Sysmex Corporation Cancer Minimal Residual Disease Testing Major Product Offerings
7.17.4 Sysmex Corporation Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.17.5 Sysmex Corporation Key News & Latest Developments
7.18 Genetron Health
7.18.1 Genetron Health Company Summary
7.18.2 Genetron Health Business Overview
7.18.3 Genetron Health Cancer Minimal Residual Disease Testing Major Product Offerings
7.18.4 Genetron Health Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.18.5 Genetron Health Key News & Latest Developments
8 Global Cancer Minimal Residual Disease Testing Production Capacity, Analysis
8.1 Global Cancer Minimal Residual Disease Testing Production Capacity, 2018-2029
8.2 Cancer Minimal Residual Disease Testing Production Capacity of Key Manufacturers in Global Market
8.3 Global Cancer Minimal Residual Disease Testing Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Cancer Minimal Residual Disease Testing Supply Chain Analysis
10.1 Cancer Minimal Residual Disease Testing Industry Value Chain
10.2 Cancer Minimal Residual Disease Testing Upstream Market
10.3 Cancer Minimal Residual Disease Testing Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Cancer Minimal Residual Disease Testing Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
